Key facts
- AIS Biotech’s last known valuation is $6.3M (Jun 2025).
- It has raised $1.7M; the latest was Early Stage VC ($1.7M) in Jun 2025.
- Notable investors include Linksium.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AIS Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for AIS Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AIS Biotech
Operator of a biotechnology company intended to revolutionize the prevention and treatment of infectious diseases through nature-inspired, sugar-based biotherapies. The company offers a proprietary bioengineering platform that develops sugar-based anti-infective agents mimicking natural pathogen receptors, enabling customers to combat viral and bacterial infections with therapies that are sustainable, non-toxic and resistant to antimicrobial resistance.
- Sector
- Healthcare
- HQ
- Grenoble, France
- Founded
- 2023
- Employees
- 5
- Website
- ais-biotech.com/
- Ownership
- Privately Held (backing)
AIS Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AIS Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AIS Biotech in its N-PORT filings yet. We sweep new filings monthly.